S
SLD
vs
S
S&P/ASX 300
Over the past 12 months, SLD has underperformed S&P/ASX 300, delivering a return of -67% compared to S&P/ASX 300's +2% growth.
Stocks Performance
SLD vs S&P/ASX 300
Performance Gap
SLD vs S&P/ASX 300
Performance By Year
SLD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Saluda Medical Inc
Glance View
Saluda Medical Inc is a US-based company operating in industry. The company is headquartered in Bloomington, Minnesota. The company went IPO on 2025-12-05. Saluda Medical, Inc. is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company’s closed-loop, dose-control platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback. The company is focused on leveraging its platform to disrupt and grow the spinal cord stimulation (SCS) market for chronic pain. The Company’s product, Evoke System, is designed to treat chronic neuropathic pain by providing SCS therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. The Evoke System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable lower back pain and leg pain.
